Abstract:Over 90% of venous thromboembolism (VTE) in children are provoked by transient risk factors and are associated with a very low risk for recurrence (∼1%).[1] Nevertheless, children with a history of VTE and persistent prothrombotic risk factors such as, but not limited to, central venous catheters (CVCs), thrombophilia, and cancer, have an increased risk for recurrent VTE,[2] [3] [4] [5] ranging from 16 to 29% in previous studies.[3] [4] [5] [6] [7] [8] Prospective multicenter data on the use of secondary anticoagulation in patients with a first provoked VTE and persistent or recurrent risk factors are limited. The objective of this study was to characterize secondary anticoagulation use and clinical outcomes in children < 21 years old with provoked VTE. We conducted a secondary analysis of the National Institutes of Health (NIH)-sponsored, multinational Kids-DOTT parallel-cohort randomized controlled trial (RCT; NCT00687882)[1] on duration of anticoagulation for the treatment of acute provoked VTE in patients < 21 years old. The trial was approved by the local institutional review board or research ethics committee at each of the 42 participating sites in Australia, Austria, Canada, the Netherlands, and the United States. The Kids-DOTT trial enrolled 532 children ages 0 to <21 years with a first provoked VTE from 2008 to 2021. Full details of the trial design and eligibility criteria have been previously published.[1] The trial protocol permitted the use of secondary anticoagulation at prophylactic dosing at the discretion of the treating clinician for persistent prothrombotic risk factors following the randomized duration of primary anticoagulation ("extended secondary anticoagulation") or for episodes of transient recurrence of prothrombotic risk factors over the course of the 2-year follow-up period ("episodic secondary anticoagulation"). For this study, we defined extended secondary anticoagulation as any continuation of anticoagulation after the completion of primary anticoagulation treatment. Episodic secondary anticoagulation was defined as anticoagulation that began ≥ 2 weeks after primary anticoagulation was completed. We reviewed all anticoagulant treatment case report forms and extracted details specific to secondary anticoagulant use. Data were summarized as counts and percentages for categorical variables and medians with interquartile ranges (IQR) for continuous variables. To compare groups who did, versus who did not, receive secondary anticoagulation, Mann–Whitney U test was used for continuous variables and chi-square or Fisher's exact test for categorical variables. A p- value of ≤0.05 was considered significant. Statistical analyses were performed using R version 4.1.2 (R Core Team, 2021) and SAS software version 9.4 (Cary, NC). Among 532 participants enrolled in the Kids-DOTT parallel-cohort RCT, 13 (2.4%) were prescribed secondary anticoagulation. Characteristics of participants who did versus did not receive secondary anticoagulation are shown in [Table 1]. Participants who received secondary anticoagulation were older than those who did not (median: 12.8 years [IQR: 7.5–14.18] vs. 7.84 years [0.95–15.1], p = 0.3), but the difference was not statistically significant. Sex, race, and ethnicity did not differ significantly between groups. Variable Overall N = 532[a] No secondary anticoagulation N = 519[a] Secondary anticoagulation N = 13[a] p -Value[b] Age (y) 0.3 Mean 8.26 8.2 10.6 Median (IQR) 7.97 (0.02–20.91) 7.84 (0.95–15.1) 12.77 (7.5–14.18) Sex 0.96 Female 249 (47%) 243 (47%) 6 (46%) Male 283 (53%) 276 (53%) 7 (54%) Race 0.48 American Indian or Alaskan Native 2 (0.4%) 2 (0.4%) 0 (0%) Asian 16 (3.0%) 16 (3.1%) 0 (0%) Black or African American 69 (13%) 68 (13%) 1 (8%) White or Caucasian 385 (72%) 374 (73%) 11(85%) Multiple 5 (9%) 4 (1%) 1 (8%) Other 14 (2.4%) 14 (3%) 0 (0%) Unknown/not reported 41 (7.7%) 41(8%) 0 (11%) Index VTE anatomical site 0.01 Cerebral sinovenous thrombosis 75 (14%) 73 (14%) 2 (15%) 0.70 Lower extremity DVT ± PE 242 (45%) 240 (46%) 2 (15%) 0.04 Renal vein thrombosis 2 (0.4%) 1 (0.2%) 1(8%) 0.05 Right atrial thrombosis 2 (0.4%) 2 (0.4%) 0 (0%) 1.00 Splanchnic vein thrombosis 7 (13%) 6 (1%) 1(8%) 0.16 Upper extremity DVT ± PE 157 (30%) 150 (29%) 7 (54%) 0.07 Other VTE site 46 (9%) 46 (9%) 0 (0%) 0.62 Not reported 1(0.2%) 1 (0.2%) 0 (0%) 1.00 Provoking factor for index VTE Central venous catheter 237 (44%) 229 (49%) 8 (73%) 0.22 Infection 145 (27%) 141 (27%) 4 (31%) 0.69 Trauma or surgery within previous 30 d 92 (17%) 90 (17%) 2 (15%) 0.65 Unspecified 52 (10%) 52 (10%) 0(0%) 0.29 Other 48 (9%) 47 (9%) 1 (8%) -Abstract Truncated-

Mechanical Thromboprophylaxis and Hospital-Acquired Venous Thromboembolism Among Critically Ill Adolescents: A U.S. Pediatric Health Information Systems Registry Study, 2016–2023

Model-Guided Decision-Making for Thromboprophylaxis and Hospital-Acquired Thromboembolic Events Among Hospitalized Children and Adolescents: The CLOT Randomized Clinical Trial

Thromboprophylaxis for children hospitalized with COVID-19 and MIS-C

Hospital-Acquired Venous Thromboembolism and Invasive Mechanical Ventilation: A Report From the Children's Hospital Acquired Thrombosis Consortium

Incidence, risk factors, and treatment patterns for deep venous thrombosis in hospitalized children: an increasing population at risk

Hospital-associated venous thromboembolism prophylaxis use by risk assessment at a large integrated health care network in Northern California

Proportion and risk factors for hospital-acquired venous thromboembolism in children: a systematic review and meta-analysis of data from 20 million individuals in 22 countries

Factors associated with venous thromboembolism pharmacoprophylaxis initiation in hospitalized medical patients: the Medical Inpatients Thrombosis and Hemostasis study

Overuse and underuse of thromboprophylaxis in medical inpatients

Shifting Paradigm In Physician Practice Patterns In The Application Of Thromboprophylaxis Guidelines: An Updated Analysis Of Venous Thromboembolism Prevention At a University-Affiliated Tertiary Care Center

Age-specific trends in intravenous thrombolysis and mechanical thrombectomy utilization in acute ischemic stroke in children under age 18

Secondary Anticoagulation Use in Patients

Practice variation in venous thromboembolism prophylaxis in adolescent trauma patients: A comparative analysis of pediatric, adult, and mixed trauma centers

Pre-hospital Tourniquet Use in Adolescent and Pediatric Traumatic Hemorrhage: A National Study

Trends in the Diagnosis of Pediatric Venous Thromboembolism and Arterial Ischemic Stroke during the COVID-19 Pandemic: An Administrative Database Study

Preventing venous thrombosis in critically ill children: what is the right approach?

Comprehensive secondary analysis of thrombotic events in pediatric patients receiving extracorporeal membrane oxygenation: A prospective cohort study

Risk of Venous Thromboembolism in Adolescents Undergoing Pelvic Osteotomy: Insights From a Propensity-matched Retrospective Cohort Study

Impact of Clinical Decision Support with Mandatory versus Voluntary Venous Thromboembolism Risk Assessment in Hospitalized Patients

Screening and Prophylaxis for Venous Thromboembolism in Pediatric Surgery: A Systematic Review

Intravenous thrombolysis for treatment of pediatric acute ischemic stroke: Analysis of 20 years of population-level data in the United States